Sangamo Therapeutics, Inc. (0R1D.L)
USD 0.57
(-11.67%)
USD 0.57
(-11.67%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 165.32 Million USD | -70.61% |
| 2022 | 562.5 Million USD | -22.08% |
| 2021 | 721.92 Million USD | -23.08% |
| 2020 | 938.55 Million USD | 47.22% |
| 2019 | 637.51 Million USD | 7.98% |
| 2018 | 590.39 Million USD | 105.9% |
| 2017 | 286.74 Million USD | 81.61% |
| 2016 | 157.89 Million USD | -27.32% |
| 2015 | 217.23 Million USD | -10.68% |
| 2014 | 243.21 Million USD | 72.69% |
| 2013 | 140.83 Million USD | 70.64% |
| 2012 | 82.53 Million USD | -5.5% |
| 2011 | 87.33 Million USD | 38.63% |
| 2010 | 62.99 Million USD | -27.95% |
| 2009 | 87.43 Million USD | 28.87% |
| 2008 | 67.85 Million USD | -19.13% |
| 2007 | 83.9 Million USD | 50.41% |
| 2006 | 55.78 Million USD | 13.88% |
| 2005 | 48.98 Million USD | 41.06% |
| 2004 | 34.72 Million USD | -24.89% |
| 2003 | 46.23 Million USD | -17.78% |
| 2002 | 56.22 Million USD | -33.86% |
| 2001 | 85.01 Million USD | 23.35% |
| 2000 | 68.92 Million USD | 649.18% |
| 1999 | 9.2 Million USD | 128.17% |
| 1998 | 4.03 Million USD | -41.53% |
| 1997 | 6.89 Million USD | 1179.41% |
| 1996 | 539 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 93.01 Million USD | -27.87% |
| 2024 Q1 | 128.96 Million USD | -21.99% |
| 2023 Q2 | 325.07 Million USD | -26.21% |
| 2023 FY | 165.32 Million USD | -70.61% |
| 2023 Q4 | 165.32 Million USD | -24.75% |
| 2023 Q1 | 440.56 Million USD | -21.68% |
| 2023 Q3 | 219.69 Million USD | -32.42% |
| 2022 FY | 562.5 Million USD | -22.08% |
| 2022 Q2 | 617.12 Million USD | -5.68% |
| 2022 Q1 | 654.31 Million USD | -9.37% |
| 2022 Q3 | 593.91 Million USD | -3.76% |
| 2022 Q4 | 562.5 Million USD | -5.29% |
| 2021 Q2 | 835.36 Million USD | -4.76% |
| 2021 Q1 | 877.09 Million USD | -6.55% |
| 2021 FY | 721.92 Million USD | -23.08% |
| 2021 Q4 | 721.92 Million USD | -6.53% |
| 2021 Q3 | 772.39 Million USD | -7.54% |
| 2020 Q1 | 584.27 Million USD | -8.35% |
| 2020 Q3 | 963.71 Million USD | 7.72% |
| 2020 Q4 | 938.55 Million USD | -2.61% |
| 2020 FY | 938.55 Million USD | 47.22% |
| 2020 Q2 | 894.65 Million USD | 53.12% |
| 2019 Q4 | 637.51 Million USD | -0.42% |
| 2019 Q3 | 640.22 Million USD | -4.94% |
| 2019 Q2 | 673.48 Million USD | 24.09% |
| 2019 Q1 | 542.72 Million USD | -8.07% |
| 2019 FY | 637.51 Million USD | 7.98% |
| 2018 Q4 | 590.39 Million USD | -2.67% |
| 2018 FY | 590.39 Million USD | 105.9% |
| 2018 Q3 | 606.6 Million USD | -3.36% |
| 2018 Q2 | 627.72 Million USD | 123.26% |
| 2018 Q1 | 281.16 Million USD | -1.94% |
| 2017 Q3 | 269.79 Million USD | -4.67% |
| 2017 Q2 | 282.99 Million USD | 92.76% |
| 2017 Q4 | 286.74 Million USD | 6.28% |
| 2017 FY | 286.74 Million USD | 81.61% |
| 2017 Q1 | 146.81 Million USD | -7.02% |
| 2016 Q2 | 180.9 Million USD | -8.19% |
| 2016 FY | 157.89 Million USD | -27.32% |
| 2016 Q4 | 157.89 Million USD | -4.3% |
| 2016 Q3 | 164.97 Million USD | -8.8% |
| 2016 Q1 | 197.04 Million USD | -9.29% |
| 2015 FY | 217.23 Million USD | -10.68% |
| 2015 Q1 | 238.5 Million USD | -1.94% |
| 2015 Q2 | 229.94 Million USD | -3.59% |
| 2015 Q4 | 217.23 Million USD | -6.57% |
| 2015 Q3 | 232.51 Million USD | 1.12% |
| 2014 Q1 | 255.5 Million USD | 81.41% |
| 2014 Q2 | 250.83 Million USD | -1.83% |
| 2014 FY | 243.21 Million USD | 72.69% |
| 2014 Q3 | 247.34 Million USD | -1.39% |
| 2014 Q4 | 243.21 Million USD | -1.67% |
| 2013 Q1 | 75.84 Million USD | -8.1% |
| 2013 Q4 | 140.83 Million USD | 0.34% |
| 2013 FY | 140.83 Million USD | 70.64% |
| 2013 Q3 | 140.36 Million USD | 89.18% |
| 2013 Q2 | 74.19 Million USD | -2.17% |
| 2012 FY | 82.53 Million USD | -5.5% |
| 2012 Q4 | 82.53 Million USD | 0.88% |
| 2012 Q3 | 81.81 Million USD | -5.21% |
| 2012 Q2 | 86.31 Million USD | -4.55% |
| 2012 Q1 | 90.42 Million USD | 3.54% |
| 2011 FY | 87.33 Million USD | 38.63% |
| 2011 Q4 | 87.33 Million USD | -1.1% |
| 2011 Q3 | 88.31 Million USD | -7.65% |
| 2011 Q2 | 95.62 Million USD | 82.01% |
| 2011 Q1 | 52.53 Million USD | -16.61% |
| 2010 Q4 | 62.99 Million USD | -4.39% |
| 2010 FY | 62.99 Million USD | -27.95% |
| 2010 Q1 | 79.35 Million USD | -9.25% |
| 2010 Q2 | 72.1 Million USD | -9.14% |
| 2010 Q3 | 65.88 Million USD | -8.62% |
| 2009 Q3 | 51.38 Million USD | -6.47% |
| 2009 FY | 87.43 Million USD | 28.87% |
| 2009 Q4 | 87.43 Million USD | 70.17% |
| 2009 Q2 | 54.93 Million USD | -9.76% |
| 2009 Q1 | 60.87 Million USD | -10.28% |
| 2008 Q2 | 75.93 Million USD | -1.05% |
| 2008 Q4 | 67.85 Million USD | -4.1% |
| 2008 FY | 67.85 Million USD | -19.13% |
| 2008 Q1 | 76.74 Million USD | -8.53% |
| 2008 Q3 | 70.74 Million USD | -6.83% |
| 2007 Q4 | 83.9 Million USD | -2.83% |
| 2007 Q1 | 50.54 Million USD | -9.38% |
| 2007 Q3 | 86.34 Million USD | 83.96% |
| 2007 Q2 | 46.93 Million USD | -7.14% |
| 2007 FY | 83.9 Million USD | 50.41% |
| 2006 Q1 | 44.05 Million USD | -10.07% |
| 2006 Q3 | 58.29 Million USD | -4.11% |
| 2006 Q2 | 60.79 Million USD | 38.02% |
| 2006 Q4 | 55.78 Million USD | -4.32% |
| 2006 FY | 55.78 Million USD | 13.88% |
| 2005 FY | 48.98 Million USD | 41.06% |
| 2005 Q3 | 24.65 Million USD | -9.85% |
| 2005 Q2 | 27.34 Million USD | -11.26% |
| 2005 Q1 | 30.81 Million USD | -11.25% |
| 2005 Q4 | 48.98 Million USD | 98.7% |
| 2004 Q2 | 40.36 Million USD | -6.71% |
| 2004 Q1 | 43.26 Million USD | -6.42% |
| 2004 FY | 34.72 Million USD | -24.89% |
| 2004 Q3 | 36.35 Million USD | -9.92% |
| 2004 Q4 | 34.72 Million USD | -4.49% |
| 2003 Q3 | 48.1 Million USD | -3.88% |
| 2003 FY | 46.23 Million USD | -17.78% |
| 2003 Q2 | 50.04 Million USD | -5.07% |
| 2003 Q4 | 46.23 Million USD | -3.89% |
| 2003 Q1 | 52.72 Million USD | -6.24% |
| 2002 Q2 | 77.2 Million USD | -4.35% |
| 2002 Q1 | 80.71 Million USD | -5.06% |
| 2002 FY | 56.22 Million USD | -33.86% |
| 2002 Q3 | 56.02 Million USD | -27.43% |
| 2002 Q4 | 56.22 Million USD | 0.36% |
| 2001 FY | 85.01 Million USD | 23.35% |
| 2001 Q4 | 85.01 Million USD | -2.16% |
| 2001 Q3 | 86.89 Million USD | 32.67% |
| 2001 Q2 | 65.5 Million USD | -3.59% |
| 2001 Q1 | 67.94 Million USD | -1.43% |
| 2000 Q1 | 22.95 Million USD | 0.0% |
| 2000 FY | 68.92 Million USD | 649.18% |
| 2000 Q2 | 69.79 Million USD | 204.11% |
| 2000 Q4 | 68.92 Million USD | -0.19% |
| 2000 Q3 | 69.05 Million USD | -1.05% |
| 1999 FY | 9.2 Million USD | 128.17% |
| 1998 FY | 4.03 Million USD | -41.53% |
| 1997 FY | 6.89 Million USD | 1179.41% |
| 1996 FY | 539 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 80.122% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 82.359% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 78.747% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 0.111% |
| bluebird bio, Inc. | 619.16 Million USD | 73.299% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -31.369% |
| Imunon, Inc. | 21.91 Million USD | -654.264% |
| Editas Medicine, Inc. | 499.15 Million USD | 66.88% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.38% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 95.073% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 86.208% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 94.915% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 88.267% |
| Verastem, Inc. | 149.71 Million USD | -10.421% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.796% |
| Waters Corporation | 4.62 Billion USD | 96.427% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.833% |
| Biogen Inc. | 26.84 Billion USD | 99.384% |
| Nektar Therapeutics | 398.03 Million USD | 58.466% |
| Perrigo Company plc | 10.8 Billion USD | 98.471% |
| Dynavax Technologies Corporation | 997.09 Million USD | 83.42% |
| Illumina, Inc. | 10.11 Billion USD | 98.365% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -484.74% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 78.815% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 25.701% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -151.667% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 97.584% |
| Evolus, Inc. | 188.99 Million USD | 12.528% |
| Adicet Bio, Inc. | 207.29 Million USD | 20.249% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 16.253% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.5% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 19.668% |
| FibroGen, Inc. | 423.52 Million USD | 60.966% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 98.464% |
| OPKO Health, Inc. | 2.01 Billion USD | 91.782% |
| Homology Medicines, Inc. | 47.05 Million USD | -251.319% |
| Geron Corporation | 394.07 Million USD | 58.049% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 95.683% |
| Exelixis, Inc. | 2.94 Billion USD | 94.381% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 55.136% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -7.082% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 87.293% |
| Zoetis Inc. | 14.28 Billion USD | 98.843% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 71.896% |
| Abeona Therapeutics Inc. | 64 Million USD | -158.304% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.273% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -195.483% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 94.471% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 94.936% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 73.401% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 90.462% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 84.244% |
| Insmed Incorporated | 1.32 Billion USD | 87.568% |
| TG Therapeutics, Inc. | 329.58 Million USD | 49.84% |
| Incyte Corporation | 6.78 Billion USD | 97.562% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 90.99% |